Osaka, Japan

Hirohisa Suidou

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Sunstar Inc.. Active years: 2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hirohisa Suidou. Retrieved from https://idiyas.com/inventor/hirohisa-suidou

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hirohisa Suidou: Innovator in Peptide Research

Introduction

Hirohisa Suidou is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of peptide research, particularly in the development of novel compounds with therapeutic potential. His work focuses on innovations that can impact health and medicine.

Latest Patents

Hirohisa Suidou holds a patent for "Tripeptides having angiotensin converting enzyme inhibitory activity and uses thereof." This patent describes a novel peptide with ACE inhibitory activity, specifically a tripeptide consisting of Leu-Arg-Ala. This innovation has potential applications in treating conditions related to hypertension and cardiovascular health.

Career Highlights

Suidou's career is marked by his dedication to research and development in the field of biochemistry. His work has led to advancements in understanding how specific peptides can influence biological processes. His innovative approach has garnered attention in both academic and industrial circles.

Collaborations

Hirohisa Suidou has collaborated with notable colleagues, including Kousaku Ohinata and Yuutarou Ogawa. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.

Conclusion

Hirohisa Suidou's contributions to peptide research exemplify the impact of innovation in the field of health and medicine. His work continues to pave the way for new therapeutic possibilities.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…